Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  Progressive Digital Media Group PLC       GB00B1GCQP32

News SummaryMost relevantAll newsSector newsTweets

GlobalData : Global HER2-positive breast cancer market to face challenges from biosimilars through to 2025

share with twitter share with LinkedIn share with facebook
share via e-mail
08/01/2017 | 05:11pm CET

The human epidermal growth factor receptor type 2 (HER2)-positive breast cancer space across the eight major markets of the US, France, Germany, Italy, Spain, the UK, Japan, and China, which is set to hit $9.89 billion in 2025, is likely to face barriers due to the introduction of new biosimilars, according to research and consulting firm GlobalData.

The company's latest report states that the long-anticipated launch of oncology biosimilars in 2017 will be closely watched as drug makers expect to struggle with biosimilar erosion of their own biologics. In the HER-2-positive breast cancer market, the EU and Japan patents protecting Herceptin expired in 2014, meaning that biosimilar trastuzumab can enter the marketplace, while the drug's patent in the US will not expire until 2019.

Maxime Bourgognon, Ph.D., PharmD, Senior Healthcare Analyst for GlobalData explains: 'Trastuzumab biosimilars are now under review with the EMA and FDA, and the first biosimilar was filed for approval in Japan in April 2017. Considering the generally high uptake of biosimilars in the European markets, the launch of trastuzumab biosimilars is expected to have a significant effect on the market landscape.

'While physicians across all markets remain cautious when extrapolating clinical bioequivalence data, payers are expected to support switching to the cheaper alternative. Despite the growing portfolio of other HER2-targeted agents, this could be the first significant challenge to Roche's stronghold on the market.'

However, GlobalData believes the impact that trastuzumab biosimilars will have on the HER2-positive breast cancer space could be limited in markets where subcutaneous Herceptin was already sold at a cheaper price to its intravenous counterpart.

Bourgognon continues: 'Biosimilars are expected to have a negative effect on drug sales in established markets where Herceptin use has reached saturation. However, in China, where the high cost of Herceptin has hindered patient access, the launch of trastuzumab is expected to encourage more widespread use of the drug in in HER2-positive breast cancer care.'

- Information based on GlobalData's report: Pharmapoint: HER2-Positive Breast Cancer - Global Drug Forecast and Market Analysis to 2025.

GlobalData plc published this content on 01 August 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 01 August 2017 15:11:02 UTC.

share with twitter share with LinkedIn share with facebook
share via e-mail
12/12 GLOBALDATA : Multiple sclerosis disease-modifying therapies market to reach $25 ..
12/11 GLOBALDATA : China will remain world’s largest bottled water market to 202..
12/06 GLOBALDATA : 2017 average monthly mobile data usage in Europe to hit 2.4GB
12/05 GLOBALDATA : Toys R Us UK stores rejuvenation is the key to future growth
12/05 GLOBALDATA : Buyer beware as bitcoin investors see a $2,000 fall in 24 hours
12/04 GLOBALDATA : The state of experiential retail in 5 charts
11/29 GLOBALDATA : Offshore wealth management sees adjustments with CRS rule
11/28 GLOBALDATA : Manufacturers need to focus on innovation to avoid ‘villain&r..
11/24 GLOBALDATA : Mobile data costs vary greatly across Europe, with Belgium and the ..
11/21 GLOBALDATA : Premium beer consumption in Vietnam more than doubled between 2011 ..
More news
Financials ( GBP)
Sales 2017 118 M
EBIT 2017 -
Net income 2017 -
Debt 2017 20,5 M
Yield 2017 1,34%
P/E ratio 2017 -
P/E ratio 2018 -
Capi. / Sales 2017 5,14x
Capi. / Sales 2018 -
Capitalization 587 M
Income Statement Evolution
Michael Thomas Danson Chief Executive Officer
Bernard Anthony Cragg Chairman
Simon John Pyper Chief Financial Officer
Peter Martin Harkness Independent Non-Executive Director
Murray Legg Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
RELX18.15%47 204
RELX N.V.19.92%47 202
S&P GLOBAL INC59.21%43 784
EQUIFAX INC.-0.70%14 232